The GSK sales force is expected to begin promoting VYVANSE to physicians in May 2009. The agreement is based on profit-sharing above an agreed-upon baseline figure.
VYVANSE, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 4 million VYVANSE prescriptions have been filled, bringing the current US market share to nearly 12 percent based on weekly branded prescription volume. Additionally, VYVANSE formulary coverage has been positive, with nine of Shire's top 11 managed care organizations covering the product in a preferred formulary position.
VYVANSE is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.
Additional information about VYVANSE and Full Prescribing Information, including Medication Guide, are available at http://www.vyvanse.com.
VYVANSE is indicated for the treatment of ADHD. Efficacy based on two controlled trials in children aged 6 to 12 and one controlled trial in adults.
Tell the doctor about any heart conditions, including structural
abnormalities, that you, your child, or a family member, may have. Inform the
doctor immediately if you or your child develops symptoms that suggest hear
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved